Navigation Links
Chinese Medical Device Market Worth $53.5 billion by 2020 Says a New Research Report at RnRMarketResearch.com
Date:10/23/2013

Dallas, TX (PRWEB) October 24, 2013

The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.

Considerable investment in China’s pharmaceutical Research & Development (R&D) sector, along with numerous government-initiated reforms, will spark soaring growth in the country’s pharmaceutical market in the near future. China is the most populated country in the world. In 2012, its population was approximately 1.3 billion, approximately one fifth of the global population. Growth has however been effectively controlled and has slowed down due to the strict enforcement of family-planning and one-child policies. The decline in the size of the young working-age group and the growing elderly population are however matters of concern for policy planners.

Complete report is available at http://www.rnrmarketresearch.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-china-market-report.html .

According to the company’s latest report on China’s healthcare industry CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – China, the country’s pharmaceutical market value will climb from an estimated $48 billion in 2012 to a massive $315 billion in 2020, at a Compound Annual Growth Rate (CAGR) of 26.5%. This increase will see China’s pharmaceutical market become the second largest in the world, with surging revenue propelling industry value significantly closer to that of the US, which GlobalData forecasts to reach $475 billion in 2020.

An expanding and aging population will also play a key role in boosting China’s pharmaceutical market revenue. With the country’s elderly population expected to account for 19% of its total population of 1.41 billion in 2020, GlobalData expects to see a rising prevalence of chronic diseases, which will in turn spark an increasing demand for treatment. This factor will also be a primary driver behind the rising value of China’s medical device market – the second largest in Asia, behind Japan – which forecasts will climb from $20 billion in 2012 to $54 billion in 2020.

This report identifies the key trends in China’s healthcare market, providing insights into the demographic, regulatory and reimbursement landscape and the country’s healthcare infrastructure, as well as the trends and segmentation of the Chinese pharmaceutical and medical device markets.

Scope

The report provides information on the healthcare, regulatory and reimbursement landscape in China, and includes:

Overview of the pharmaceutical and medical devices markets, comprising market size, segmentation, and key drivers and barriers;

Profiles and SWOT analysis of the major players in the pharmaceutical market, of which the major Multinational Companies (MNCs) were GlaxoSmithKline (GSK), Pfizer, and AstraZeneca; and the major domestic players were Harbin Pharmaceutical Group and Tasly Pharmaceutical Group; and the medical device market, of which the major players were Siemens Healthcare, GE Healthcare, Fresenius Medical Care, GlaxoSmithKline, and Philips Healthcare;

Insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, regulatory agencies, and market authorization processes for new drugs and medical devices;

Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure, and healthcare expenditure;

An overview of the opportunities for and challenges to growth in the Chinese healthcare market.

Reasons to buy

This report will enhance your decision-making capability by allowing you to:

Develop business strategies by understanding the trends shaping and driving China’s healthcare market;

Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical and medical devices market segments, and companies likely to impact the healthcare market in the future;

Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors;

Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investments, and strategic partnerships;

Identify, understand and capitalize on the opportunities and challenges in China’s healthcare market.

Purchase a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=111444.

Browse more reports on Regulation Market: http://www.rnrmarketresearch.com/reports/life-sciences/healthcare/regulation-policy/regulation.

Contact sales(at)rnrmarketresearch(dot)com for further information.

About Us:
RnRMarketResearch.com (http://www.rnrmarketresearch.com/) is an online database of market research reports that offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at http://www.prweb.com/releases/healthcare-regulatory/reimbursement-china/prweb11260851.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Combining Chinese and Western medicine could lead to new cancer treatments
2. Chinese Orthopedic Biomaterials Market
3. Chinese OTC Drug Industry 2013 Analysis and 2017 Forecasts in New Research Report at RnRMarketResearch.com
4. Chinese Contract Research Organization Market (CRO) 2013 Analysis in New Research Report at RnRMarketResearch.com
5. 123Greetings Launched Spanish, Chinese, Russian, & Hindi Ecards Under World Languages, Adding Diversity To Its Collection
6. Chinese Traditional Clothing with Discounts Now Online at 4leafcity.com
7. Chinese CDC and Aeras sign agreement to collaborate on TB vaccine R&D
8. UCLA and Chinese scientists analyze genetic makeup of human and mouse embryos in amazing detail
9. 4leafcity.com Has Launched a Promotional Offer on Chinese Traditional Dresses
10. International Food Protection Training Institute Hosts Chinese Delegation
11. Daily QiGong and Chinese Medicine Improves Health Says Alternative Medicine Pioneer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... ... its executive team as the President of its HealthBI division. McFarland will ... and contact centers. , “Scott is a utility player who balances his ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has introduced a ... When we’re born, Nature gives us a full supply of melanin – in the ... lose this natural glare-reducing pigment; however, around the age of thirty, we develop a ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... the present, Mirixa Corporation recently unveiled the MirixaPro 6.0 platform. As the ... how medication management services are delivered. Based on industry research and market ...
(Date:9/19/2017)... ... September 19, 2017 , ... Back Pain Centers of ... back pain with a reputable physician in their area, announces the addition of ... as Nevada Spine Clinic was founded by board-certified spine surgeon, Jaswinder Grover, M.D. ...
(Date:9/19/2017)... ... 2017 , ... The ISO 9001 standard sets out the requirements for a ... and improve customer satisfaction. ISO 9001:2015 was released in 2015 and certified organizations have ... September 2018. , As described in this white paper , ISO ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/9/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... lasmiditan, an investigational, oral, first-in-class molecule for the acute ... to placebo in the Phase 3 SPARTAN study. Detailed ... of the International Headache Society (IHC) in ... demonstrate lasmiditan,s potential to reduce pain and provide freedom ...
(Date:9/7/2017)... Caris Life Sciences, a leading innovator ... of precision medicine, today announced results from two ... molecular profiling approach in guiding therapeutic strategies in ... (CGP+) with Caris Molecular Intelligence ® to ... level, leading to more therapeutic options and improved ...
Breaking Medicine Technology: